newsfilter
← Earnings
Earnings Releases·

Invivyd — Third Quarter 2026 Earnings Summary

  • Q3 2026 net product revenue rose 18% year-over-year to $15.4 million, while total operating costs and expenses increased 107% to $50.1 million, resulting in a net loss of $33.5 million ($0.10 per share) versus $10.5 million ($0.06 per share) in Q3 2025.
  • Cash and cash equivalents declined to $126.4 million as of September 30, 2026, from $226.7 million at year-end 2025, driven by elevated R&D and SG&A expenses associated with the DECLARATION and LIBERTY trials.
  • The DECLARATION Phase 3 trial data for VYD2311 is expected imminently to support a BLA submission under the Accelerated Approval Program, following LIBERTY Phase 3 results demonstrating superior safety and tolerability compared to mRNA vaccines.
  • Management anticipates a shift toward increased operating efficiency post-REVOLUTION program spend and plans a 2027 investor event to detail commercial strategies, though PEMGARDA's EUA is scheduled to terminate on June 29, 2027.
  • The company initiated the FLINTLOCK Phase 2 trial in October 2026 to evaluate VYD2311 for Long COVID and Post-Vaccination Syndrome, while production scaling for the measles candidate VMS063 continues to support 2027 clinical development.
Company
INVIVYD INC
Sector
Healthcare
Industry
Biotechnology